Unknown Primary Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-01-26
Clinical Trial Update: A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) [Phase 2]
A phase 2 trial evaluating nab-paclitaxel-based doublet as first-line therapy for cancer of unknown primary (unknown primary tumors).